Capital Impact Advisors, LLC Apellis Pharmaceuticals, Inc. Transaction History

Capital Impact Advisors, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$76.68 - $93.31 $641,044 - $780,071	-8,360 Reduced 60.0%	5,574 $507,000
Q1 2023 May 23, 2023	SELL	$46.59 - $66.96 $1,164 - $1,673	-25 Reduced 0.18%	13,934 $919,000
Q3 2022 Nov 21, 2022	BUY	$44.76 - $69.66 $29,496 - $45,905	659 Added 4.95%	13,959 $604,000
Q2 2022 Aug 15, 2022	BUY	$35.07 - $59.21 $466,431 - $787,493	13,300 New	13,300 $601,000

299

111M

2.63M

845K

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.67B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Capital Impact Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Capital Impact Advisors, LLC with notifications on news.